Tag Archives: PE

China PE Firm Invests Up to $40M Per Company In Medtech, Diagnostics, and Digital Health

19 Jul

A private equity firm headquartered in China with additional offices throughout China and Hong Kong provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Hong Kong PE Firm Seeks to Invest Up to $10 M in Clinically Validated Medical Device and Diagnostics Products with China Angle

12 Jul

A PE firm that is headquartered in Hong Kong with additional offices throughout China currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Chinese VC/PE Firm Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential

17 May

A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Healthcare-Focused VC and PE Fund Invests in North American Companies in Therapeutics, Medical Devices, Digital Health and Services

5 Apr

A private equity and venture fund is currently focused on health care investments such as therapeutics, medical devices, health care services, and digital health companies. The firm likes to invest early, generally seed-series A, as one of the earliest investors, and be involved throughout the life of the company, helping it grow and develop. The firm invests primarily in companies in North America. The firm will generally invest $250,000-$2M in the initial investment, with the potential for continuing funding. Because the firm prefers to play an active role in their portfolio companies, the firm will only invest in a limited number of companies at any given time.

The firm primarily invests in therapeutics and medical devices. Because the firm prefers to invest early, they look at companies that are still pre-clinical/in development and, for devices, will consider PMA as well as 510k devices. The firm is indication agnostic, focusing on technologies that inspire their passion. The firm will consider investing in technologies related to orphan diseases.

The firm has no specific management team requirements. Due to the firm’s active role in their portfolio companies, the firm does like to take a board seat following the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: PE Firm with Offices in North America Invests & Provides Advisory Support to Medical and Surgical Devices and Healthcare IT Companies

29 Mar

A private equity firm founded in 2014 with offices in USA and Canada manages a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year.

The firm works closely with clients of the firm’s advisory arm that provides companies with financial, strategic, and growth consulting and transaction advisory services including M&A. The firm will also help companies through regulatory approvals and developing new strategic and financial partnerships. The firm will consider companies that are outside of this network, but it is important that these companies form a close long-term relationship with the firm in leveraging their development. This integrated network provides for superior insight and strategy of lower risk. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor 1: VC/PE Investment Firm Backed by China and Taiwan Companies Invests Broadly Across Seed and Post-Seed Stage Life Science Companies

22 Mar

A venture capital and private equity firm based in Cambridge, MA provides seed capital out of an angel group subsidiary within the firm, and also provides equity to later stage IT (robotics, AI, IoT, new materials, FinTech, etc.) and healthcare companies. The firm is backed by five public pharmaceutical companies and ten public IT and healthcare companies from Taiwan and China. The angel group subsidiary provides up to $2M seed stage investments in early-stage companies, while the parent firm provides equity of $2M – $5M per company post seed stage. The firm is also actively looking for PE and M&A opportunities worldwide in the $1B ~ 5B range. The firm seeks companies on a global level, though has a focus in Boston and North America East Coast-based companies.

Within healthcare, the firm is interested in biotech therapeutics, medical devices, healthcare IT and digital health. The firm is opportunistic in subsector and indication and has a specific interest in oncology products. For healthcare IT, the firm is interested in software, AI, robotics, and digital health technology that seeks to integrate into hospital systems. For medical devices, the firm is interested in drug delivery system devices that require a therapeutic component. The firm typically seeks companies that already have CE Mark, FDA, CFDA, or TFDA approval.

The firm requires the management team to have technical expertise in their field of study, and prefers companies that also have business development expertise. The firm typically takes a board seat after an investment, but at the minimum will maintain a close relationship with the entrepreneur as a support and advisor. The firm typically participates in two financing rounds per company, and also supports the company in finding add-on investors for the following round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: